title: Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India.
abstract: OBJECTIVE
  Uterine myoma is a common indication for hysterectomy in India. An effective medical treatment option may reduce hysterectomy associated morbidity. This study was undertaken to evaluate efficacy and safety of low dose mifepristone in medical management of myoma and to compare two doses - 10 vs. 25 mg/day.
  
  
  METHODS
  In this randomized clinical trial, women with symptomatic myoma or myoma>5 cm were included. Uterine size >20 wk, fibroids >15 cm were excluded. Pictorial blood loss assessment chart (PBAC) score was used to assess menstrual-blood-loss and visual analog scale (VAS) for other symptoms. Haemogram, liver function test, ultrasound with doppler and endometrial histology was performed. Patients were randomized and were given oral mifepristone as 25 mg/day in group 1 and 10 mg/day in group 2 for 3 months. Patients were followed at 1, 3 and 6 months.
  
  
  RESULTS
  Seventy patients in group 1 and 73 in group 2 completed treatment. Mean PBAC score reduced from 253 to 19.8 and from 289.2 to 10.4 at 1 and 3 months in groups 1 and 2, respectively. At 3 months, 67 of 70 (95.7%) patients of group 1 and 66 of 73 (90.4%) of group 2 developed amenorrhoea which reverted after median 34 (range 4-85) days. Mean myoma volume decreased by 35.7 per cent (from 176.8 to 113.7 cm 3 ) and 22.5 per cent (from 147.6 to 114.4 cm 3 ) at 3 months in groups 1 and 2, respectively. Side effects seen were leg cramps in 7 of 70 (10%) and 5 of 73 (6.8%) and hot-flushes in 5 of 70 (7.1%) and 5 of 73 (6.8%) in groups 1 and 2, respectively. Repeat endometrial-histopathology did not reveal any complex hyperplasia or atypia in either group.
  
  
  CONCLUSIONS
  Mifepristone (10 and 25 mg) caused symptomatic relief with more than 90 per cent reduction in menstrual blood. Greater myoma size reduction occured with 25 mg dose. Amenorrhoea was developed in 90-95 per cent patients which was reversible. It can be a reasonable choice for management of uterine leiomyoma as it is administered orally, cost-effective and has mild side effects.
authors.affiliation: Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Vidushi
authors.initials: V
authors.lastname: Kulshrestha
authors.forename: Alka
authors.initials: A
authors.lastname: Kriplani
authors.forename: Nutan
authors.initials: N
authors.lastname: Agarwal
authors.forename: Neetu
authors.initials: N
authors.lastname: Sareen
authors.forename: Pradeep
authors.initials: P
authors.lastname: Garg
authors.forename: Smriti
authors.initials: S
authors.lastname: Hari
authors.forename: Jyoti
authors.initials: J
authors.lastname: Thulkar
mesh_terms: D000284:Administration, Oral; D000328:Adult; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006727:Hormone Antagonists / Q000008:administration & dosage; D006801:Humans; D007194:India; D007889:Leiomyoma / Q000188:drug therapy*; D008595:Menorrhagia / Q000188:drug therapy; D008875:Middle Aged; D015735:Mifepristone / Q000008:administration & dosage*; D011446:Prospective Studies; D062606:Tertiary Care Centers; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy*
chemical_list: D006727:Hormone Antagonists; D015735:Mifepristone